局限性前列腺癌的局灶治疗:高强度聚焦超声或冷冻消融的单中心经验
该单中心回顾性队列纳入2009至2018年接受高强度聚焦超声或冷冻消融局灶治疗的309例低/中危局限性前列腺癌患者,中位随访45个月,1、3、5年无失败生存率分别为95%、67%、54%,5年无转移生存率98%,无前列腺癌特异性死亡。术前活检Gleason评分7(3+4)或以上及最低前列腺特异性抗原为治疗失败的独立预测因素。
要点
- 5年无失败生存率54%,近半数患者5年后无局灶治疗失败。
- 术前活检Gleason评分7(3+4)或以上(HR 2.4)与最低PSA(HR 2.2)为失败独立预测因素。
- 补救性局灶治疗中,原发局灶治疗后原位复发与更差的无失败生存相关(p=0.02)。
核心结论
- 近半数男性在局灶治疗后5年无治疗失败,但中位随访期间仍有相当比例出现复发。
- 术前活检Gleason评分和最低前列腺特异性抗原与治疗失败显著相关。
研究设计与样本
- 单中心回顾性队列分析2009至2018年接受局灶治疗(高强度聚焦超声或冷冻消融)的局限性前列腺癌患者309例。
- 局灶治疗适用于低或中危疾病(前列腺特异性抗原小于20 ng/ml、Gleason评分7或以下、临床分期T2b或以下)。
- 排除既往接受前列腺癌治疗或随访不足6个月的患者。
主要发现
- 309例中190例接受高强度聚焦超声、119例接受冷冻消融,中位随访45个月。
- 1、3、5年无失败生存率分别为95%、67%、54%,无根治性治疗生存率分别为99%、79%、67%。
- 5年无转移生存率为98%,队列中无前列腺癌特异性死亡。
- 术前活检Gleason评分7(3+4)或以上(HR 2.4,p<0.001)与最低前列腺特异性抗原(HR 2.2,p<0.001)为局灶治疗失败的独立相关因素。
- 补救性局灶治疗中,原发局灶治疗后原位复发与更差的无失败生存相关(p=0.02)。
关键数值与推荐
- 失败定义为接受局部或全身补救治疗、非治疗患者活检Gleason评分7或以上(原位或非原位)、前列腺癌转移或前列腺癌特异性死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report oncologic outcomes in patients treated with focal therapy for prostate cancer. MATERIALS AND METHODS: We retrospectively analyzed a single institution cohort of men with localized prostate cancer who received focal therapy using high intensity focused ultrasound or cryotherapy from 2009 to 2018. Focal therapy was offered for low or intermediate risk disease (prostate specific antigen less than 20 ng/ml, Gleason score 7 or less and clinical stage T2b or less). Patients with previous prostate cancer treatment or less than 6 months of followup were excluded from study. Failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death. Cox regression analysis was done to identify independent predictors of failure after focal therapy. RESULTS: Of the 309 patients included in study 190 and 119 were treated with high intensity focused ultrasound and cryotherapy, respectively. Median followup was 45 months. At 1, 3 and 5 years the failure-free survival rate was 95%, 67% and 54%, and the radical treatment-free survival rate was 99%, 79% and 67%, respectively. The 5-year metastasis-free survival rate was 98% and no prostate cancer specific death was registered in this cohort. Before focal therapy a biopsy Gleason score of 7 (3 + 4) or greater (HR 2.4, p <0.001) and nadir prostate specific antigen (HR 2.2, p <0.001) were independently associated with failed focal therapy. In the salvage focal therapy setting in-field recurrence after primary focal therapy was associated with poorer failure-free survival (p=0.02). CONCLUSIONS: Almost half of the men were free of focal therapy failure 5 years after treatment. Still, a significant proportion experienced recurrence at the midterm followup. The preoperative biopsy Gleason score and nadir prostate specific antigen were significantly associated with treatment failure.
引用
- Tourinho-Barbosa RR, Sanchez-Salas R, Claros OR, et al. Focal Therapy for Localized Prostate Cancer with Either High Intensity Focused Ultrasound or Cryoablation: A Single Institution Experience. J Urol. 2019. PMID: 31437121. doi:10.1097/JU.0000000000000506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。